Skip to main content

Month: January 2024

Quadient Announces Appointment of New Chief Marketing Officer, Petra Wolf

Petra WolfPetra Wolf, CMO at QuadientQuadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer connections through digital and physical channels, today announced the appointment of Petra Wolf as new Chief Marketing Officer, effective January 2, 2024. With a professional journey spanning more than 20 years, Petra Wolf has excelled in senior management positions within the spheres of B2B and B2C technology marketing. Her seasoned expertise extends across various tech-related industries, encompassing semi-conductors, server and client hardware, consulting, and software development. Prior to joining Quadient, Petra successfully steered Global Marketing for Small and Medium Businesses at Amazon Web Services, where she demonstrated her ability to identify and capitalize on market opportunities through...

Continue reading

DIVERGENT Energy Services Announces Closing of Shares for Interest Transaction

CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) — DIVERGENT Energy Services Corp. (the “Corporation“) announces that it has closed its shares for interest transaction by electing to satisfy the interest obligation on its debentures (“Debentures“) in the amount of $36,232.88 due on December 31, 2023 (the “Interest Obligation“) by the issuance of 1,767,458 common shares of the Corporation (“Common Shares“) at a deemed price of $0.0205 per Common Share to the holders of Debentures. The transaction is subject to the final approval of the TSX Venture Exchange (“TSXV“) and is pursuant to the Corporation’s right to satisfy its interest obligation owed on the Debentures. The Common Shares issued pursuant to the Interest Obligation are subject to the minimum pricing rules...

Continue reading

Check Point Software to Announce Fourth Quarter and Full Year 2023 Financial Results on February 6, 2024

SAN CARLOS, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, today announced that it will release its financial results for the fourth quarter and full year 2023 ended December 31, 2023, on Tuesday, February 6, 2024, before the U.S. financial markets open. Management will host a video conference call with the investment community at 8:30 AM EDT/5:30 AM PST on February 6, 2024. A live video webcast of the call will be hosted on the company’s website at http://www.checkpoint.com/ir. To follow this and other Check Point news visit:Twitter: http://www.twitter.com/checkpointsw Facebook: http://www.facebook.com/checkpointsoftware Blog: http://blog.checkpoint.com/ YouTube: http://www.youtube.com/user/CPGlobal LinkedIn: https://www.linkedin.com/company/check-point-software-technologiesAbout...

Continue reading

Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA. The live and archived webcast can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. About Intra-Cellular Therapies Intra-Cellular Therapies is a biopharmaceutical...

Continue reading

EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer

   LYON, France, January 2, 2024 – EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the Company has appointed Ken Mobeck as its Chief Financial Officer of EDAP worldwide, and Francois Dietsch as Global Chief Accounting Officer. Both appointments are effective as of January 1, 2024. “Over the past year, we have continued to align our organization in support of our strategic growth initiatives to build shareholder value by focusing on expanding our operational and commercial presence in the U.S.,” said Ryan Rhodes, Chief Executive Officer of EDAP. “Based on Ken’s extensive experience in global finance, investor relations and operations, this appointment to Global Chief Financial Officer is consistent with our ongoing alignment and will enable EDAP to remain focused on executing...

Continue reading

CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024

NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that its President and Chief Executive Officer, Sujal Shah, will present at the upcoming 42nd Annual JP Morgan Healthcare Conference taking place January 8 -11 in San Francisco, California.42nd Annual JP Morgan Healthcare ConferenceDate:     Wednesday, January 10, 2024Time:     4:30pm PT/ 7:30pm ETLocation:     Grand Ballroom, The Westin St. Francis Hotel, San FranciscoWebcast:     http://ir.cymabay.com/eventsAbout CymaBayCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical...

Continue reading

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight  disease, dosed the first patient in the Phase I/II trial in men with metastatic castration-resistant prostate cancer (mCRPC) on December 27, 2023. INKmune™ is a biologic therapy given as out-patient therapy without the need for pre-medication or cytokine support. “Results of immunotherapy trials for mCRPC have been disappointing,” said Professor Matt Rettig, Professor of Medicine and Urology, Medical Director of the Prostate Cancer Program at the David Geffen School of Medicine at UCLA and member of the Jonsson Comprehensive Cancer Center. “After many failures using T-cell focused immunotherapy...

Continue reading

Provident Financial Services, Inc. Schedules Fourth Quarter and Year-End Earnings Conference Call

ISELIN, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) — Provident Financial Services, Inc. (NYSE: PFS) announced that it expects to release financial results for the quarter and year ended December 31, 2023 on Thursday, January 25, 2024 after market close. A copy of the earnings release will be immediately available on the Company’s website, www.Provident.Bank, by going to Investor Relations and clicking on Press Releases. Representatives of the Company will hold a conference call for investors on January 26, 2024 at 10:00 a.m. (ET) to discuss the Company’s fourth quarter and full year financial results. Information about the conference call is as follows:Participant Toll-Free Dial-In Number: 1-888-412-4131Participant Toll Dial-In Number: 1-646-960-0134Conference ID: 3610756Internet access to the call will be available (listen...

Continue reading

Hydrofarm Holdings Group to Participate in the 2024 ICR Conference

SHOEMAKERSVILLE, Pa., Jan. 02, 2024 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, today announced that the Company will participate in a fireside chat discussion at the 2024 ICR Conference in Orlando, Florida. Hydrofarm’s discussion will begin at 2:00 PM ET on Monday, January 8, 2024. This fireside chat will be webcast live and available for replay on the corporate website at www.hydrofarm.com, under the “Investors” section, or directly through the ICR Conference website at www.icrconference.com. About Hydrofarm Holdings Group, Inc.Hydrofarm is a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for...

Continue reading

Freshpet, Inc. to Participate in the 2024 ICR Conference

SECAUCUS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) — Freshpet, Inc. (“Freshpet” or the “Company”) (NASDAQ:FRPT) today announced that members of the executive management team will participate in the 2024 ICR Conference in Orlando, FL. The presentation will be on Monday, January 8, 2024 at 11:30 a.m. ET and can be accessed over the Internet and hosted on the “Investors” section of the Company’s website at www.freshpet.com. About FreshpetFreshpet’s mission is to improve the lives of dogs and cats through the power of fresh, real food. Freshpet foods are blends of fresh meats, vegetables and fruits farmed locally and made at our Freshpet Kitchens. We thoughtfully prepare our foods using natural ingredients, cooking them in small batches at lower temperatures to preserve the natural goodness of the ingredients. Freshpet...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.